EMFLAZA® is the first and only corticosteroid FDA-approved to treat Duchenne muscular dystrophy
EMFLAZA has been shown to preserve muscle strength and function
In a clinical trial of 196 boys aged 5 to 15 with Duchenne muscular dystrophy, the effectiveness and safety of EMFLAZA was compared with placebo (sugar pills) and prednisone.
- EMFLAZA improved muscle strength at 12 weeks compared with placebo
- EMFLAZA was numerically favoreda in timed measures of patient function:
- These findings were not considered statistically significant. This means that because the two groups studied were not large enough, the results could have occurred by chance.
In additional studies, deflazacort preserved muscle strength and function better than prednisone
Deflazacort improved muscle strength compared with prednisone
In a clinical study of 196 patients with Duchenne muscular dystrophy aged 5 to 15 years:
- Deflazacort preserved muscle strength better than placebo by Week 12
- Deflazacort preserved and improved muscle strength better than prednisone from Week 12 to 52
Deflazacort was shown to delay disease progression by years
In a study to observe the long-term effects of steroids:
Loss of ability to stand from a lying-on-the-back position—delayed by 2.1 years when compared with prednisone
Loss of ambulation (ability to walk)—delayed by 2.7 years when compared with prednisone
Loss of hand-to-mouth function with retained hand function—delayed by 2.7 years when compared with prednisone
Deflazacort is associated with later loss of ambulation compared with prednisone
Click here to see more about the studies that support this information.